Tests trastuzumab deruxtecan after surgery for HER2-expressing endometrial cancer
Tests trastuzumab deruxtecan against standard chemotherapy in adults with HER2-expressing endometrial cancer.
Key facts
- Who runs it
- Daiichi Sankyo
- Where
- Daegu and Seoul, South KoreaSee the 3 sitesAlso in 14 other countries, 127 sites
- Trial code
- Registry title
- A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 710 people, planned
- Started
- 30 Sept 2025
- Expected to end
- 23 Mar 2032
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Trastuzumab Deruxtecan
- Chemotherapy
- Record updated
- 27 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women newly diagnosed with endometrial cancer (Stage IIC or III) who have had surgery and have HER2-expressing tumors (IHC 3+/2+).
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Newly diagnosed epithelial endometrial cancer, FIGO 2023 Stage IIC (including Stage IICmp53abn) or Stage III. Carcinosarcomas can join; pure sarcomas cannot.
- Earlier treatment
- No earlier anticancer treatment (this includes treatment given before surgery). The trial tests treatment given after surgery.
- Biomarker or test result
- The tumor must be HER2-expressing (IHC 3+/2+). Enough stored tumor tissue must be available for testing by a central laboratory.
Main reasons for not taking part
- Uterine mesenchymal tumors or pure sarcomas, including adenosarcomas
- Recurrent cancer or FIGO 2023 Stage IV
- Tumor left over after surgery
- Known POLE mutation
- Serious heart problems, such as a heart attack in the last 6 months or symptomatic heart failure
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Adults ≥18 years at the time the ICF is signed (Please follow local regulatory requirements if the legal age of consent for trial participation is >18 years old)
- Has histologically confirmed diagnosis of epithelial endometrial carcinoma. All histology's are allowed except for sarcomas (carcinosarcomas are allowed)
- Is newly diagnosed FIGO 2023 Stage IIC (including Stage IICmp53abn) or Stage III Note: FIGO 2023 Stage IIC includes disease with aggressive histological types (aggressive histological types are composed of high-grade EECs (grade 3), serous, clear cell, undifferentiated, mixed, mesonephric-like, gastrointestinal mucinous type carcinomas, and carcinosarcomas) with any myometrial involvement. FIGO 2023 Stage III includes disease with local and/or regional spread of the tumor of any histological subtype
- Has HER2-expression (IHC 3+/2+)
- Has adequate archived tumor tissue sample available for assessment of HER2 status by central laboratory
Who cannot take part
- Has residual tumor after surgery as determined by BICR assessment
- Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the trial enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion, etc.) and any autoimmune, connective tissue, or inflammatory disorder with potential pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc.), or prior pneumonectomy
- Has a history of (noninfectious) ILD/pneumonitis that required corticosteroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at SCR
- Has a medical history of MI within 6 months before randomization/enrollment, symptomatic CHF (NYHA Class II to IV). Participants with troponin levels above ULN at SCR (as defined by the manufacturer), and without any MI related symptoms should have a cardiologic consultation during SCR Period to rule out MI
- Has uterine mesenchymal tumor such as an endometrial stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas. Adenosarcomas are also not allowed
- Has recurrent or FIGO 2023 Stage IV
- Is known to have a POLE mutation from an approved and/or validated local test, according to local regulations, if available
- Has a QTcF prolongation to > 480 msec based on average of the SCR triplicate12-lead ECG
Where in South Korea
Also in 14 other countries, 127 sites
- Keimyung University Dongsan HospitalDaegu, South KoreaTaking people
- Samsung Medical CenterSeoul, South KoreaTaking people
- Seoul National University HospitalSeoul, South KoreaTaking people
About the trial
What the trial wants to find out
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.
The 2 groups in the trial
- Arm A: T-DXdTreatment being tested
Participants will receive T-DXd 5.4 mg/kg intravenously (IV) once every 3 weeks (Q3W) with or without \[optional\] radiotherapy
Treatment: Trastuzumab Deruxtecan
- Arm B: Standard of Care ChemotherapyExisting treatment, for comparison
Participants will receive carboplatin AUC 5 or 6 and paclitaxel 175 mg/m2 Q3W, or AUC 5 or 6 and paclitaxel 175 mg/m2 Q3W with or without \[optional\] radiotherapy or chemoradiotherapy (EBRT plus cisplatin \[as radiosensitizer\] 50 mg/m2
Treatment: Chemotherapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)
- Plain-language title
- Tests trastuzumab deruxtecan after surgery for HER2-expressing endometrial cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 27 October 2026